Catalent to Present at International Cell Engineering Conference
Released
on: December 2, 2008, 5:31 am
Press Release Author: Dan Dunlop
Industry:
Biotech
Press
Release Summary: Dr. Greg Bleck, the senior director of cell line
engineering at Catalent Pharma Solutions, will present this week
at the 2nd International Cell Engineering Conference to be held
in Santa Barbara, C.A., December 2-4, 2008.
Press
Release Body: Research Triangle Park, N.C., December 1, 2008 –
Dr. Greg Bleck, the senior director of cell line engineering
at Catalent Pharma Solutions, will present this week
at the 2nd International Cell Engineering Conference to
be held in Santa Barbara, C.A., December 2-4, 2008. The
conference will include presentations by leading pharmaceutical
companies, small biotech organizations, academics, and key technology
supply firms covering the latest advancements in cell line development.
Special emphasis will be placed on the reliability and reproducibility
of the more promising cell engineering techniques. The conference
is produced by the Williamsburg BioProcessing Foundation.
Dr.
Bleck's presentation is titled "Generation of Stable-High
Expressing Mammalian Cell Lines in Four Months without Antibiotic
Selection or Gene Amplification Using GPEx®."
Catalent’s proprietary GPEx® technique
for cell line engineering allows high-expressing, genetically
stable cells for any mammalian cell type to be produced without
antibiotic selection or gene amplification. The lack of selection
and amplification allows these master cell bank candidate cell
lines to be made in four months, and permits research and development
scientists to contemplate new paths for improved expression of
their proteins. The candidate cell lines range in specific productivities
from 30-95 picograms/cell/day for antibodies and have reached
as high as 50-70 picograms/cell/day for some recombinant protein
producing cell lines. Cell lines producing over 150 different
antibodies and 40 different recombinant proteins have been developed
with GPEx®. Data showing the consistency
and speed of the technology, as well as the stability and productivity
of the cell lines will be presented.
About
Catalent
Headquartered
in Somerset, New Jersey, Catalent is one of the leading providers
of advanced dose form and packaging technologies, and development,
manufacturing and packaging services for pharmaceutical, biotechnology
and consumer health companies in nearly 100 countries. Catalent
applies its local market expertise and technical creativity to
advance treatments, change markets and enhance patient outcomes.
Catalent employs approximately 9,500 at more than 30 facilities
worldwide and generates more than $1.8 billion of annual revenue.
For more information, visit www.catalent.com.
Web
Site: http://www.catalent.com
Contact
Details: Dan Dunlop, Jennings PR
104-A North Elliott Road
Chapel Hill, NC 27514
Phone 919-929-0225
Fax 919-968-8278
ddunlop@jenningsco.com
2012
